Editorial
The changing world of drug development
Chinese Clinical Oncology
2014;
3
(2)
:12
.
(30 May 2014)
Review Article
The spectrum of clinical trials aiming at personalizing medicine
Chinese Clinical Oncology
2014;
3
(2)
:13
.
(30 May 2014)
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine
Chinese Clinical Oncology
2014;
3
(2)
:14
.
(30 May 2014)
Integrative oncology drug discovery accompanied by preclinical translational research as prerequisite for clinical development
Chinese Clinical Oncology
2014;
3
(2)
:15
.
(30 May 2014)
From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
Chinese Clinical Oncology
2014;
3
(2)
:16
.
(30 May 2014)
Functional and molecular imaging in cancer drug development
Chinese Clinical Oncology
2014;
3
(2)
:17
.
(30 May 2014)
New challenge of developing combined radio-drug therapy
Chinese Clinical Oncology
2014;
3
(2)
:18
.
(30 May 2014)
The changing world of drug development: an academic research organization’s perspective on the “Seven Wonders” of the future world of anticancer drug development
Chinese Clinical Oncology
2014;
3
(2)
:19
.
(30 May 2014)
The changing world of oncology drug development—A global pharmaceutical company’s perspective
Chinese Clinical Oncology
2014;
3
(2)
:20
.
(30 May 2014)
Medicine adaptive pathways to patients (MAPPs): using regulatory innovation to defeat Eroom’s law
Chinese Clinical Oncology
2014;
3
(2)
:21
.
(30 May 2014)
The changing world of cancer drug development: the regulatory bodies’ perspective
Chinese Clinical Oncology
2014;
3
(2)
:22
.
(30 May 2014)
The positioning of economic principles under the changing conditions of the novel drug developmental process in cancer
Chinese Clinical Oncology
2014;
3
(2)
:23
.
(30 May 2014)
And now for something completely different: drugs that work!—The patients’ perspective
Chinese Clinical Oncology
2014;
3
(2)
:24
.
(30 May 2014)
Disclosure:
The focused issue “The Changing World of Drug Development” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Christian Dittrich served as the unpaid Guest Editor for the focused issue.
